Bone mineral density utilization in patients with newly diagnosed multiple myeloma.
Muchtar E et al. Hematol Oncol. 2016 Jun 21. doi: 10.1002/hon.2303. [Epub ahead of print].

Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.
D’Souza A et al. Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14170. [Epub ahead of print].

Galectin-8 enhances adhesion of multiple myeloma cells to vascular endothelium and is an adverse prognostic factor.
Friedel M et al. Glycobiology. 2016 Jun 10. pii: cww066. [Epub ahead of print].

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.
Nikesitch N et al. Blood Cancer J. 2016 Jun 10;6:e432. doi: 10.1038/bcj.2016.40.

Imaging Manifestations of Hematologic Diseases with Renal and Perinephric Involvement.
Purysko AS et al. Radiographics. 2016 Jun 3:150213. [Epub ahead of print].

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.
Bochtler T et al. Blood. 2016 Jun 2. pii: blood-2015-10-676361. [Epub ahead of print].

Expression of MAGE-C1/CT7 provides prognostic information in multiple myeloma.
Xu P et al. Leuk Lymphoma. 2016 Jun 1:1-3. [Epub ahead of print].

(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.
Regelink JC et al. EJNMMI Res. 2016 Dec;6(1):46. doi: 10.1186/s13550-016-0197-4. Epub 2016 May 31.

Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma.
Szabo AG et al.Leuk Lymphoma. 2016 May 31:1-9. [Epub ahead of print].

Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines.
Kamińska J et al. Pol Arch Med Wewn. 2016 May 31;126(5):321-9. doi: 10.20452/pamw.3427. Epub 2016 May 31.

The Prognostic Significance of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Patients WithMultiple Myeloma.
Wongrakpanich S et al. J Clin Lab Anal. 2016 May 30. doi: 10.1002/jcla.22004. [Epub ahead of print].

Centrosome associated genes pattern for risk sub-stratification in multiple myeloma.
Kryukov F et al. J Transl Med. 2016 May 28;14(1):150. doi: 10.1186/s12967-016-0906-9.

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.
Majithia N et al. Leukemia. 2016 Jun 7. doi: 10.1038/leu.2016.147. [Epub ahead of print].